These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 17614825

  • 21. High-dose intravenous chelation therapy with deferoxamine.
    Cohen A, Mizanin J, Schwartz E.
    Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model.
    Chan GC, Ng DM, Fong DY, Ha SY, Lau YL.
    Am J Hematol; 2004 Aug; 76(4):398-404. PubMed ID: 15282678
    [Abstract] [Full Text] [Related]

  • 24. Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy.
    Obejero-Paz CA, Yang T, Dong WQ, Levy MN, Brittenham GM, Kuryshev YA, Brown AM.
    J Lab Clin Med; 2003 Feb; 141(2):121-30. PubMed ID: 12577048
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Clinical and economic burden of infused iron chelation therapy in the United States.
    Payne KA, Desrosiers MP, Caro JJ, Baladi JF, Lordan N, Proskorovsky I, Ishak K, Rofail D.
    Transfusion; 2007 Oct; 47(10):1820-9. PubMed ID: 17880607
    [Abstract] [Full Text] [Related]

  • 28. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
    Porter JB, Rafique R, Srichairatanakool S, Davis BA, Shah FT, Hair T, Evans P.
    Ann N Y Acad Sci; 2005 Oct; 1054():155-68. PubMed ID: 16339661
    [Abstract] [Full Text] [Related]

  • 29. Long term audiological evaluation of beta-thalassemic patients.
    Kontzoglou G, Koussi A, Economou M, Tsatra I, Perifanis V, Noussios G, Athanassiou-Metaxa M.
    Acta Otorhinolaryngol Belg; 2004 Oct; 58(2):113-7. PubMed ID: 15515654
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Successful desensitization of a case with desferrioxamine hypersensitivity.
    Gülen F, Demir E, Tanaç R, Aydinok Y, Gulen H, Yenigün A, Can D.
    Minerva Pediatr; 2006 Dec; 58(6):571-4. PubMed ID: 17093379
    [Abstract] [Full Text] [Related]

  • 32. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
    Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M, Nakao S, Nakahata T, Harada M, Murate T, Ozawa K, Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes.
    Eur J Haematol; 2007 Jun; 78(6):487-94. PubMed ID: 17391310
    [Abstract] [Full Text] [Related]

  • 33. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR, De Sanctis V, Gilli G.
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
    [Abstract] [Full Text] [Related]

  • 34. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
    Di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S, Angelucci E.
    Eur J Haematol; 2007 Jun; 78(6):540-2. PubMed ID: 17391307
    [Abstract] [Full Text] [Related]

  • 35. Iron chelating in thalassaemia with left ventricular dysfunction.
    Cagirci G, Tufekcioglu O, Yetim M.
    Heart; 2006 Oct; 92(10):1440. PubMed ID: 16973798
    [No Abstract] [Full Text] [Related]

  • 36. Oral iron chelators.
    Nathan DG, Piomelli S.
    Semin Hematol; 1990 Apr; 27(2):83-5. PubMed ID: 2190320
    [No Abstract] [Full Text] [Related]

  • 37. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study.
    Osborne RH, De Abreu Lourenço R, Dalton A, Houltram J, Dowton D, Joshua DE, Lindeman R, Ho PJ.
    Value Health; 2007 Apr; 10(6):451-6. PubMed ID: 17970927
    [Abstract] [Full Text] [Related]

  • 38. Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs.
    Yokel RA, Ackrill P, Burgess E, Day JP, Domingo JL, Flaten TP, Savory J.
    J Toxicol Environ Health; 1996 Aug 30; 48(6):667-83. PubMed ID: 8772805
    [Abstract] [Full Text] [Related]

  • 39. Deferasirox Novartis.
    Barton JC.
    Curr Opin Investig Drugs; 2005 Mar 30; 6(3):327-35. PubMed ID: 15816510
    [Abstract] [Full Text] [Related]

  • 40. Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results.
    Thuret I, Hacini M, Pégourié-Bandelier B, Gardembas-Pain M, Bisot-Locard S, Merlat-Guitard A, Bachir D.
    Hematology; 2009 Dec 30; 14(6):315-22. PubMed ID: 19941737
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.